Background: In 'real-life', the Nordic score guides Erythropoietic stimulating agent (ESA) use in
| I N T R O D U C T I O N
Erythropoietic stimulating agents (ESAs) are the mainstay treatment of lower risk anemic patients with myelodysplastic syndromes (MDS), with reported response rates of 27%-50% [1] [2] [3] and response durations that range from 12-24 months. 4 In case control studies, the use of ESAs in lower risk MDS patients is associated with improved overall survival [4] [5] [6] primarily in lower risk patients who respond to ESA therapy.
In a randomized controlled trial compared with best supportive care,
ESA use was associated with improved quality of life and improved overall survival in responding patients. 7 The heterogeneity in responsiveness to ESA has led to efforts to develop tools that allow identification of patients most and least likely to respond. Factors identified as predictive of response include lower endogenous erythropoietin (EPO) levels, marrow blasts < 10%, international prognostic scoring system (IPSS) low and int-1, French American British (FAB) MDS subtype refractory anemia, normal karyotype, transfusion independence, and short duration of disease. 8 The most commonly employed predictive score for ESA (1 granulocyte colony stimulating factor [G-CSF]) use is that of the Nordic group, a weighted scoring system developed in 1997 comprising 2 elements: erythropoietin level (< 100 IU/L, 100-500 IU/L, and > 500 IU/L) and 2 levels of red blood cell (RBC) transfusion dependence (< 2 units vs 2 u/4 weeks). The response criteria in Scandinavia included complete and partial responses (CR 1 PR). The model, derived from 98 evaluable patients divided patients into 3 predictive risk categories for responses of 7%, 25%, and 74%. 9 This scoring system has been validated by other groups. [10] [11] [12] Importantly, as a result of this scoring system, patients with endogenous erythropoietin levels greater than 500 IU/L are rarely offered ESA trials and ESA's are typically offered to patients with scores of 21 and higher (Overall response rate, ORR, 25%-74%). Clinical predictive scores that include aberrant immunophenotype on myeloid blasts have been proposed 13 but these were developed in small groups of patients and are limited in general application by the necessity for flow cytometric analysis of a recent bone marrow specimen.
Recently, alternative ESA predictive scores based on the IPSSRevised (IPSS-R), serum erythropoietin (EPO), and ferritin concentrations 14 or based on the IPSS and serum EPO concentration alone 15 were proposed and are summarized in Supporting Information Table   S5 .
In this study, using a large pooled dataset of 'real life' patients, we aimed to validate these 3 scoring systems and to develop a novel predictive ESA score to refine the predictive power of the Nordic score.
We also hoped to identify a patient subgroup whose expected ESA response rate was < 10%, for whom an ESA was likely to be futile. Institute Inc., Cary, North Carolina). In the derivation set, a scoring system for ESA response was created by assigning differential weighting according to the regression coefficients of covariates significant on multivariate analysis. The scoring system was then tested in the validation set. To identify the model with the most power to predict ESA response, we compared the categorical Nordic, IPSS-R-based, MDS-CAN, and our newly developed ESA scores using Somers' D (higher has better predictive power), Aikaike information criterion (AIC; the lower the AIC, the better the goodness-of-fit), and the G 2 likelihood ratio
| M E T H O D S
Chi-squared test (the higher the G 2 value, the better the goodness-offit). Because each of the predictive score assessments included different sample sizes due to missing variables, the G 2 likelihood value was calculated as the AIC value dropped from the null model (intercept alone) down to the fitted model (with both intercept and covariate).
Greater declines in the AIC values indicated more influence of the covariate on the model, reflected by a smaller P-value in the G 2 ratio test. All analyses were conducted using SAS. To control multiple regressions in the multivariate analysis, the multiplicity-adjusted Pvalue was calculated using the Benjamini and Hochberg approach for adjusting the false discovery rate. 23 An adjusted P-value < .05 was considered statistically significant. The MULTTEST procedure in SAS was used for adjusted P-value calculation.
| R E S U L T S
The combined sample size was 996 (FISM, n 5 555; GROM, n 5 233; and MDS-CAN, n 5 208) patients. Patient characteristics in total and grouped by registry are shown in Table 1 . The median age at ESA treatment was 76 years, with a median time from diagnosis until ESA initiation of 1.6 months (interquartile range (IQR) 0.5-7). Darbepoetin was given in 8% of patients (median dose 500 IU q 2-3 weeks, range 300-500), epoietin alpha in 78%, and epoietin beta in 14% (median dose 40 000 IU weekly score was 4 and 79% fell into the most favorable risk category (> 11).
Prior to ESA administration, 66% and 84% of patients had endogenous EPO levels < 100 U/L and < 200 U/L, respectively. The median pre-treatment serum ferritin level was 298 ug/L (IQR 145-548).
According to the IPSS, 52% and 41% fell into low and int-1 risk categories, respectively, and 83% had good risk karyotypes. By the IPSS-R classification, 75% fell into the very low and low risk groups, with 16% in the intermediate risk group. The WHO classification was not consistently available and hence is not reported. Bone marrow blast counts were < 5% in 82% of patients.
| Response
The overall response rate (ORR) to ESA in 925 patients was 59% and ranged from 46% (Canada) to 62% (Italy). The characteristics of responders and non-responders are compared in Table 2 , and by registry in online Supporting Information Table S1 . Using ESA predictive scoring systems, higher Nordic, MDS-CAN, and lower IPSS-R-based predictive scores were seen in responders than in non-responders.
Responders were more likely to be transfusion independent (66 vs 
| Derivation of the predictive score
The combined datasets were randomly divided into derivation (n 5 463) and validation (n 5 462) sets. With the exception of a longer time to ESA initiation in the validation set (1.9 vs 1.2 months, P 5.0028), the characteristics of these data sets were not statistically different (Supporting Information Table S2 ).
In the derivation set, univariate and multivariate logistic regression covariate, resulting in a scoring system of 0-3. Overall response rates were 23%, 43%, 67%, and 85% in the derivation set and 22%, 42%, 64%, and 78% in the validation set, demonstrating that the prognostic score is robust and reproducible (Table 3) . Since this was a collaborative effort between Italy and Canada, this score was named ITACA.
| Which is the best ESA predictive score?
By univariate analysis, the Nordic score, IPSS-R based, and MDS-CAN predictive scores demonstrated stratified response rates that were statistically different (Figure 1 ). The ITACA score surpassed these 3 predictive scores as evidenced by the superior Somers' D and G 2 statistics (Supporting Information Table S4 ), indicating that this score demonstrates the strongest agreement with ESA response in MDS patients.
| DISCUSSION
For the past two decades, ESAs have been the primary first line treatment for anemia in lower risk MDS, with alternatives such as 17, 27 and are associated with impaired quality of life, 28 identifying the first-line treatment most likely to result in a clinically meaningful response is important. For example, a decision analysis recommended non-growth factor (NGF) strategies as initial therapy if NGF's produced a response rate of > 46%. 29 Additionally, sub-optimal use of ESA's has been documented in a surveillance epidemiology end results program (SEER)/Medicare registry study. 30 In this new context, a more discriminating predictor of ESA response would be of great value to guide and promote adherence to therapy.
We have assembled the largest compiled international database of ESA treated patients to assess response and develop a predictive score.
In addition to patient number, the ability to derive and then validate our new score in a separate cohort with highly comparable results adds to its internal validity.
In addition to deriving the new ITACA score, we also validated the significance of our previous scoring system (MDS-CAN), the IPSS-R based score and the Nordic scores and we established that the ITACA score has the best statistically supported discriminatory capacity for predicting ESA response rates. Despite this, ITACA still has limited power to discriminate prospectively between ESA responders and nonresponders since we were unable to identify a subgroup with a predicted response rate of < 10%. We suggest that this represents an intrinsic limitation to our approach; a significant proportion of the variability in ESA response is not accounted for by the clinical and routine laboratory variables accessible for this model, and thus the negative predictive capacity of the score is still limited. In order to augment the power of the ITACA score as a predictor of ESA response, new categories of information must be incorporated. Large sample data from mutational, 31 gene expression, 32 and possibly other microenvironmental factors are potential avenues of investigation for this added value.
There are other limitations to our study. These include the inability to evaluate response according to the WHO classification since it was not included in our compiled dataset, registry derived response rates that were not centrally adjudicated, and heterogeneous dosing of ESAs, although the doses of ESA utilized in the patients analyzed were already within the ranges suggested by current international guidelines. 20 Reassuringly, the WHO classification was not found to have a significant impact on ESA response in a recent analysis, so this potential limitation to the current analysis is perhaps less significant than expected. 14 Another limitation is the low frequency of G-CSF use which may synergize with ESA's to induce an erythroid response 33, 34 although the synergistic effect between EPO and G-CSF seems to be most pronounced in low-risk MDS with ring sideroblasts, 10 a subtype that comprises only 10%-15% of all MDS. The overall response rate of 59% is higher than usually expected, although we would point out that this was a priori a selected group of patients treated in recent years whose pre-treatment Nordic scores were favorable (> 11 in 78% of 
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